Cancer Letters

Article	Citations
CD155 in tumor progression and targeted therapy	321
Accelerating the clinical translation of CD70-targeted chimeric antigen receptor-based cell therapies in oncology: A comprehensive clinical investigation panorama analysis based on the Trialtrove data	284
Tumor-derived extracellular vesicle PD-1 promotes tumor immune evasion via disruption of peripheral T cell homeostasis	242
Phase separation-based screening identifies arsenic trioxide as the N-Myc-DNA interaction inhibitor for neuroblastoma therapy	238
Corrigendum to “Lycorine promotes IDH1 acetylation to induce mitochondrial dynamics imbalance in colorectal cancer cells” [Canc. Lett. 573 (2023) 216364]	189
Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers	152
NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis	151
LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation	146
Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models	145
Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing	141
Emerging neuroimmune mechanisms in cancer neuroscience	138
Modulating the gut microbiota: A novel perspective in colorectal cancer treatment	138
NLRP3-activated bone marrow dendritic cells play antileukemic roles via IL-1β/Th1/IFN-γ in acute myeloid leukemia	125
Tertiary lymphoid structures as a biomarker in immunotherapy and beyond: Advancing towards clinical application	122
Synergistic enhancement of radio-immunotherapy efficacy by IL-15 via macrophage activation and memory T cell response	121
Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway	119
ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination	115
SF3B4-mediated alternative splicing in cancer development and progression	113
DT7 peptide-modified lecithin nanoparticles co-loaded with γ-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity	109
Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer	106
mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LS	106
Interleukin-17 activates and synergizes with the notch signaling pathway in the progression of pancreatic ductal adenocarcinoma	103
Olaparib enhances radiation-induced systemic anti-tumor effects via activating STING-chemokine signaling in hepatocellular carcinoma	98
Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression	93
The past, present, and future of liver cancer research in China	93

Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia	90
Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring	89
SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC	89
Inhibition of ribosomal RNA processing 15 Homolog (RRP15), which is overexpressed in hepatocellular carcinoma, suppresses tumour growth via induction of senescence and apoptosis	87
PA suppresses antitumor immunity of T cells by disturbing mitochondrial activity through Akt/mTOR-mediated Ca2+ flux	87
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma	86
Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries	85
Cooperation between IRTKS and deubiquitinase OTUD4 enhances the SETDB1-mediated H3K9 trimethylation that promotes tumor metastasis via suppressing E-cadherin expression	82
USP7-mediated ERβ stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma	81
Thermal-sensitive lipid nanoparticles potentiate anti-PD therapy through enhancing drug penetration and T lymphocytes infiltration in metastatic tumor	81
Expression of concern: “Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence” C	81
A novel promoter-associated non-coding small RNA paGLI1 recruits FUS/P65 to transactivate GLI1 gene expression and promotes infiltrating glioma progression	80
Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer	80
IL-1α facilitates GSH synthesis to counteract oxidative stress in oral squamous cell carcinoma under glucose-deprivation	76
Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma	75
Targeted inhibition of the expression of both MCM5 and MCM7 by miRNA-214 impedes DNA replication and tumorigenesis in hepatocellular carcinoma cells	74
Anaplastic thyroid cancer cells upregulate mitochondrial one-carbon metabolism to meet purine demand, eliciting a critical targetable vulnerability	74
Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds	74
Osteosarcoma exocytosis of soluble LGALS3BP mediates macrophages toward a tumoricidal phenotype	72
Editorial Board	70
A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma	70
Editorial Board	69
Editorial Board	68
Editorial Board	68
Editorial Board	67
Editorial Board	67
Editorial Board	66
NOS2 and COX2 predicts poor outcome in ER- breast cancer through immunosuppression. Novel Strategies to overcome immunosuppression	65
Potential Contribution of Ovarian Granulosa Cells to High-Grade Serous Ovarian Cancer Development	65
Oxysterol-Sterol Binding Proteins as Druggable Precision Targets in Ovarian Cancer	63
Precision cancer medicine in ovarian cancer	63
Lysine demethylase KDM1A/LSD1 inhibition enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer	63
Ethnic Diversity and Metabolic Variations in Ovarian Cancer Cells: Implications for Personalized Medicine Strategies	63
Aberrant Translational Mechanisms in Cancer Cells	62
Neuro-immune communication in breast cancer	61
Versatility of Exosomes for Cancer Therapy	61
Extrinsic factors associated with the response to immunotherapy in glioblastoma	59
Editorial Board	59
Colorectal cancer risk variant rs7017386 modulates two oncogenic lncRNAs expression via ATF1-mediated long-range chromatin loop	59
Editorial Board	59
Understanding cervical cancer at single-cell resolution	59
Electrochemical Immunosensor for the Detection of Circulating Tumor Cells.	59
Editorial Board	59
Letter to the editor regarding “EBV-LMP1 suppresses the DNA damage response through DNA-PK/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma”	57
Editorial Board	57
Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10	57
Axl as a potential therapeutic target for adamantinomatous craniopharyngiomas: Based on single nucleus RNA-seq and spatial transcriptome profiling	55
Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy	55
Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy	55
KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin	55

Precise delivery of celastrol by PEGylated aptamer dendrimer nanoconjugates for enormous therapeutic effect via superior intratumor penetration over antibody counterparts	54
circVAPA-rich small extracellular vesicles derived from gastric cancer promote neural invasion by inhibiting SLIT2 expression in neuronal cells	54
Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response	53
Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment	52
JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers	52
TGF-β signaling networks in the tumor microenvironment	52
LncRNAs and the cancer epigenome: Mechanisms and therapeutic potential	52
Long term outcome of prevention of liver cancer by hepatitis B vaccine: Results from an RCT with 37 years	51
c-Myc-activated intronic miR-210 and lncRNA MIR210HG synergistically promote the metastasis of gastric cancer	51
Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma	51
Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth	51
N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis	51
The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells	50
Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function	50
Efficient discovery of robust prognostic biomarkers and signatures in solid tumors	50
Corrigendum to “The long noncoding RNA LUCAT1 promotes tumorigenesis by controlling ubiquitination and stability of DNA methyltransferase 1 in esophageal squamous cell carcinoma” [Cancer Lett. (2018)	50
Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular	49
Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma	49
Nanosecond pulsed electric field stimulates CD103+ DC accumulation in tumor microenvironment via NK-CD103+ DC crosstalk	49
Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer	49
Editorial Board	47
The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes	47
Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling	46
Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies	46
Tumor-associated mesenchymal stem cells promote hepatocellular carcinoma metastasis via a DNM3OS/KDM6B/TIAM1 axis	46
Ubiquitin-specific peptidase 22 in cancer	46
PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration	45
Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression	45
Intestinal estrogen receptor beta modulates the murine colon tumor immune microenvironment	45
Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner	45
Inositol hexaphosphate enhances chemotherapy by reversing senescence induced by persistently activated PERK and diphthamide modification of eEF2	44
Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?	44
Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics	44
A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice	44
Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor	44
Gene knockout in cellular immunotherapy: Application and limitations	44
METTL3 regulates M6A methylation-modified EBV-pri-miR-BART3-3p to promote NK/T cell lymphoma growth	44
The diverse pancreatic tumor cell-intrinsic response to IFNγ is determined by epigenetic heterogeneity	43
ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation	43
Editorial Board	42
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma	42
Editorial Board	42
Editorial Board	42
Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations	42
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer	42
Pirfenidone antagonizes TGF-β1-mediated gabapentin resistance via reversal of desmoplasia and the ‘cold’ microenvironment in pancreatic cancer	41
Electroacupuncture facilitates vascular normalization by inhibiting Glyoxalase1 in endothelial cells to attenuate glycolysis and angiogenesis in triple-negative breast cancer	41
TNPO1-mediated nuclear import of ARID1B promotes tumor growth in ARID1A-deficient gynecologic cancer	40
EMP3 as a key downstream target of miR-663a regulation interferes with MAPK/ERK signaling pathway to inhibit gallbladder cancer progression	40
HDAC6-dependent deacetylation of AKAP12 dictates its ubiquitination and promotes colon cancer metastasis	40
EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition	40
Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity	40
Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives	40
Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy	40
Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead	40
Unveiling the veil of RNA binding protein phase separation in cancer biology and therapy	40
PTPRO suppresses lymph node metastasis of esophageal carcinoma by dephosphorylating MET	40
Fundamental insights and molecular interactions in pancreatic cancer: Pathways to therapeutic approaches	40
DIAPH1 mutations predict a favorable outcome for de novo MDS	40
ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer	40
Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies	40
The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer	39
Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers	39
The role of Hippo/YAP1 in cancer-associated fibroblasts: Literature review and future perspectives	39
Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study	39
ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance	39
Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells	39
FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients	38
Exosomes; multifaceted nanoplatform for targeting brain cancers	38
The tumor microenvironment's role in malignant progression and treatment response	38
Precision intervention for prostate cancer: Re-evaluating who is at risk	38
FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression	38
Lymphocyte antigen 6K signaling to aurora kinase promotes advancement of the cell cycle and the growth of cancer cells, which is inhibited by LY6K-NSC243928 interaction	38
Lysophosphatidic acid-induced amphiregulin secretion by cancer-associated fibroblasts augments cancer cell invasion	38
Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers	37
Coiled-coil domain-containing 154 promotes colorectal cancer proliferation and metastasis via interacting with minichromosome maintenance complex component 2	37
A complex of Wnt/planar cell polarity signaling components Vangl1 and Fzd7 drives glioblastoma multiforme malignant properties	37
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy	37
AMPK-mediated CD47 H3K4 methylation promotes phagocytosis evasion of glioma stem cells post-radiotherapy	37
Acidosis-induced regulation of adipocyte G0S2 promotes crosstalk between adipocytes and breast cancer cells as well as tumor progression	37

A three-stage eccDNA based molecular profiling significantly improves the identification, prognosis assessment and recurrence prediction accuracy in patients with glioma	37
Fatty acids in cancer chemoresistance	37
Poly-pharmacology of existing drugs: How to crack the code?	36
scRNA-seq of colorectal cancer shows regional immune atlas with the function of CD20+ B cells	36
CMTM6 promotes hepatocellular carcinoma progression through stabilizing β-catenin	36
Pioneering the future of cancer therapy: Deciphering the p53-ferroptosis nexus for precision medicine	36
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress	36
Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing	36
A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation	36
Clinical challenges in prostate cancer management: Metastatic bone-tropism and the role of circulating tumor cells	35
CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis	35
Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC	35
CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer	35
Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model	34
Multi-targeted therapy of cancer by omega-3 fatty acids-an update	34
Exosomal circ_0030167 derived from BM-MSCs inhibits the invasion, migration, proliferation and stemness of pancreatic cancer cells by sponging miR-338-5p and targeting the Wif1/Wnt8/β-catenin axis	34
Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma	34
IGFBP7-AS1 is a p53-responsive long noncoding RNA downregulated by Epstein-Barr virus that contributes to viral tumorigenesis	34
RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis	34
TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression	34
Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression	34
Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia	34
Loss of CD73 shifts transforming growth factor-β1 (TGF-β1) from tumor suppressor to promoter in endometrial cancer	34
CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia	33
Is it time to discard the Diagnostic and Statistical Manual of Mental Disorders (DSM) in psycho-oncology?	33
CD24 promotes metastasis and chemoresistance by directly targeting Arf6-ERK pathway in esophageal squamous cell carcinoma	33
ACLP promotes activation of cancer-associated fibroblasts and tumor metastasis via ACLP-PPARγ-ACLP feedback loop in pancreatic cancer	33
KAT7 enhances the proliferation and metastasis of head and neck squamous carcinoma by promoting the acetylation level of LDHA	33
Circular RNA circTATDN3 promotes the Warburg effect and proliferation in colorectal cancer	33
Mechanisms used by cancer cells to tolerate drug-induced replication stress	33
Hypoxia effects on glioblastoma progression through YAP/TAZ pathway regulation	33
Tuning cellular metabolism for cancer virotherapy	33
Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma	32
Fibrillarin reprograms glucose metabolism by driving the enhancer-mediated transcription of PFKFB4 in liver cancer	32
CXCL13 promotes intestinal tumorigenesis through the activation of epithelial AKT signaling	32
Direct contact between tumor cells and platelets initiates a FAK-dependent F3/TGF-β positive feedback loop that promotes tumor progression and EMT in osteosarcoma	32
Reuterin promotes pyroptosis in hepatocellular cancer cells through mtDNA-mediated STING activation and caspase 8 expression	32
Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy	32
METTL3-STAT5B interaction facilitates the co-transcriptional m6A modification of mRNA to promote breast tumorigenesis	32
Hepatocellular carcinoma and lipid metabolism: Novel targets and therapeutic strategies	32
Regulation of gut microbiota on immune cell ferroptosis: A novel insight for immunotherapy against tumor	32
Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma	32
Understanding the significance of biological clock and its impact on cancer incidence	31
METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation	31
Single-cell RNA sequencing of OSCC primary tumors and lymph nodes reveals distinct origin and phenotype of fibroblasts	31
Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth	31
Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistance	31
Mechanistic insights into genetic susceptibility to prostate cancer	31
PROTACs: Novel tools for improving immunotherapy in cancer	31
Corrigendum to “LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway” [Cancer Lett.374 (2016) 261–271]	31
Targeting the mercapturic acid pathway for the treatment of melanoma	31
Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective	31
Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway	31
Corrigendum to “SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission” [Canc. Lett. 547 (2022) 215871]	31
Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer	31
Corrigendum to “PHF14 knockdown causes apoptosis by inducing DNA damage and impairing the activity of the damage response complex in colorectal cancer” [Cancer Lett. 531 (2022) 109–123]	30
PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer	30
Immune checkpoint inhibitor resistance in hepatocellular carcinoma	30
The Landscape of Malignant Transition: Unraveling Cancer Cell-of-Origin and Heterogeneous Tissue Microenvironment	30
Corrigendum to “LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9” [Canc. Lett. 410 (2017) 68–81]	30
SUMOylated hnRNPM suppresses PFKFB3 phosphorylation to regulate glycolysis and tumorigenesis	30
Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway	30
Distinct immunophenotypic profiles and neutrophil heterogeneity in colorectal cancer	30
Corrigendum to “ 2′-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling” [Canc. Lett. 471 (2020)	30
ebv-circRPMS1 promotes the progression of EBV-associated gastric carcinoma via Sam68-dependent activation of METTL3	30
Embracing innovation and collaboration: A message from the new Editor-in-Chief	30
Jolkinolide B targets thioredoxin and glutathione systems to induce ROS-mediated paraptosis and apoptosis in bladder cancer cells	30
Evaluation and preservation of fertility in patients with hematologic malignancies	29
ASPH dysregulates cell death and induces chemoresistance in hepatocellular carcinoma	29
Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects	29
Extracellular vesicles as a novel approach for breast cancer therapeutics	29
SRSF12 deficiency enhances tumor innervation and accelerates pancreatic tumorigenesis	29
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model	29
Nervous system in colorectal cancer	29
CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer	29
Exosome-mediated transfer of SNHG7 enhances docetaxel resistance in lung adenocarcinoma	29
Epigenetic modification and tumor immunity: Unraveling the interplay with the tumor microenvironment and its therapeutic vulnerability and implications	29
Corrigendum to “HIF-2α 1 inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment” [Cancer lett. 597 (2024) 217060]	29
An emerging aspect of cancer neuroscience: A literature review on chemotherapy-induced peripheral neuropathy	29
Bypassing the Tollway; a novel path to TLR4 independent stemness regulation	29
EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer	28
Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis	28
Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies	28
Exploring shared targets in cancer immunotherapy and cancer-induced bone pain: Insights from preclinical studies	28
METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma	28
Allogeneic versus autologous hematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: a real-world multicenter analysis in China	28
Exosomal lncCRLA is predictive for the evolvement and development of lung adenocarcinoma	28
Neuron-like lineage differentiation induced by exogenous Neurexin-1 as a potential therapeutic strategy for glioma	28
Enhancing cancer radiotherapy efficacy using NanOx, a novel oxygenating perfluorocarbon nanoemulsion that reverses tumour hypoxia	28
IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors	28
Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway	28
Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer	28
H19 promotes polarization and alternative splicing in tumor-associated macrophages, facilitating pancreatic cancer progression	28
The incidence and risk of cardiovascular events associated with pembrolizumab in patients with breast cancer	28
Tumor-derived exosomes: Unravelling the pathogenesis of pancreatic cancer with liver metastases and exploring the potential for clinical translation	28